Brolucizumab
| Evidence Level: L5 | Predicted Indications: 4 |
Table of Contents
- Brolucizumab
- Brolucizumab: From Intravitreal Anti-VEGF Therapy to Mitochondrial Oxidative Phosphorylation Disorder (Nuclear DNA Anomalies)
Brolucizumab: From Intravitreal Anti-VEGF Therapy to Mitochondrial Oxidative Phosphorylation Disorder (Nuclear DNA Anomalies)
One-Sentence Summary
Brolucizumab is an anti-VEGF-A single-chain antibody fragment given by injection into the eye, marketed in the US as BEOVU. The TxGNN model predicts it may be effective for mitochondrial oxidative phosphorylation disorder due to nuclear DNA anomalies. However, there are 0 clinical trials and 0 publications supporting this prediction, so it rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Predicted New Indication | Mitochondrial oxidative phosphorylation disorder due to nuclear DNA anomalies |
| TxGNN Prediction Score | 99.67% |
| Evidence Level | L5 (model prediction only) |
| US Market Status | ✓ Marketed |
| Number of NDAs | 1 (BLA761125) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the input. Brolucizumab is known to block VEGF-A, a signal that drives new blood vessel growth and vascular leakage, and it is delivered directly into the eye. The approved indication text was also not included in the US regulatory record provided.
The review found no plausible mechanistic link between VEGF-A blockade and this predicted disease. Mitochondrial oxidative phosphorylation disorders caused by nuclear DNA anomalies are inherited defects in cellular energy production. Nothing in the available information connects them to VEGF-A signaling.
The high score of 0.997 is a graph-based output only. A high score does not by itself indicate real therapeutic potential. Because the intravitreal route also limits whole-body exposure, the prediction is hard to justify without new supporting evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| BLA761125 | BEOVU (Novartis Pharmaceuticals Corporation) | Injection, solution | Not listed in the provided data |
Safety Considerations
Please refer to the package insert for safety information. No drug interactions were found in the queried data.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no clinical trials, no literature, and no plausible mechanistic link, so the evidence level is L5. The intravitreal route further limits the drug’s use for a systemic metabolic disease. The three other predictions for this drug (esophageal varices with and without bleeding, and exocrine pancreatic insufficiency) also have no supporting evidence and are on Hold.
To proceed, the following is needed:
- Package insert warnings and contraindications, currently missing and blocking safety screening
- Mechanism of action and approved indications from DrugBank or the label
- Preclinical evidence linking VEGF-A blockade to mitochondrial oxidative phosphorylation defects
- Route compatibility assessment, since a systemic disease would need more than intravitreal delivery
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.